These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 30362224)
1. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365 [TBL] [Abstract][Full Text] [Related]
3. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. Ericsson Å; Fridhammar A J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636 [No Abstract] [Full Text] [Related]
5. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244 [TBL] [Abstract][Full Text] [Related]
6. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related]
7. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522 [TBL] [Abstract][Full Text] [Related]
8. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199 [No Abstract] [Full Text] [Related]
9. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029 [TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan. Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768 [TBL] [Abstract][Full Text] [Related]
13. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. Igarashi A; Hunt B; Wilkinson L; Langer J; Pollock RF Adv Ther; 2020 Oct; 37(10):4446-4457. PubMed ID: 32870471 [TBL] [Abstract][Full Text] [Related]
14. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
15. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy. Barrett A; Boye KS; García-Pérez LE; Giorgino F; Guerci B; Füchtenbusch M; Yu M; Sapin H; Dib A; Heitmann E; Federici MO; Lebrec J J Med Econ; 2024; 27(1):866-879. PubMed ID: 38963346 [TBL] [Abstract][Full Text] [Related]
16. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. Pollock RF; Norrbacka K; Cameron C; Mancillas-Adame L; Jeddi M J Comp Eff Res; 2019 Mar; 8(4):229-240. PubMed ID: 30644328 [TBL] [Abstract][Full Text] [Related]
17. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults. Liebisch-Rey H; Suarez-Chacon AM; Fuentes YV; Blanco J; Kock J; Lechtig-Wassermann S; Bustos RH F1000Res; 2023; 12():914. PubMed ID: 38125558 [TBL] [Abstract][Full Text] [Related]
18. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Capehorn M; Hallén N; Baker-Knight J; Glah D; Hunt B Diabetes Ther; 2021 Feb; 12(2):537-555. PubMed ID: 33423240 [TBL] [Abstract][Full Text] [Related]
19. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK. Viljoen A; Chubb B; Malkin SJP; Berry S; Hunt B; Bain SC Eur J Health Econ; 2023 Aug; 24(6):895-907. PubMed ID: 36114904 [TBL] [Abstract][Full Text] [Related]
20. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Patel D J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]